Chemotherapy alone in the treatment of patients with early stage Hodgkin's disease.
Studies employing chemotherapy in early stage Hodgkin's disease suggest that this approach is at least comparable to radiation therapy in treatment outcome. Since the long-term disease-free survival in early stages approaches 90%, it is unlikely to further improve these results substantially. Thus, the major goal is the reduction of toxicity. The future choice of therapy will be influenced by the long-term toxicity of these approaches which has to be monitored carefully.
Longo
D L
DL
Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, MD, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D009367:Neoplasm Staging